A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
The long-awaited robotic surgery system is designed to open up the market.
Two dental companies go public inside a week, with very different results.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.